Tag Archives: Paula Ragan

X4 Completes Reverse Merger with Arsanis, Looks Ahead to Phase 3 Test

X4 Pharmaceuticals is the latest biotech to join the public markets, but it didn’t follow the IPO path to get there. Cambridge, MA-based X4 said Wednesday that it completed its “reverse merger” with Arsanis (NASDAQ: ASNS). Such business combinations enable a privately held company to go public by merging with a publicly traded business. Shares […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , | Comments Off on X4 Completes Reverse Merger with Arsanis, Looks Ahead to Phase 3 Test

X4 Pharma Heads to Nasdaq Via Reverse Merger with Arsanis

A tough setback for Arsanis has given privately held X4 Pharmaceuticals the chance to go public. Arsanis (NASDAQ: ASNS) and X4, two Boston-area biotech firms, agreed Tuesday morning to merge in a deal that will enable X4 to become a publicly traded company. The combined company will keep the X4 name and be led by […]

Posted in Boston, Boston blog main, National blog main | Tagged , , , , , , , , , , , , , , , , , , , , | Comments Off on X4 Pharma Heads to Nasdaq Via Reverse Merger with Arsanis

X4 Pharma Pulls In $27M for Immune Drug in Cancer, Rare Diseases

The immune system can’t fight disease if its cells don’t reach their targets. In some cancers and rare immune deficiency disorders, immune cell levels are too low. X4 Pharmaceuticals has developed drugs that it says can help restore these counts to normal, and the company now has $27 million to test them in key clinical […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , , , , , , , , , , | Comments Off on X4 Pharma Pulls In $27M for Immune Drug in Cancer, Rare Diseases

Celebrating Boston Life Sciences: Xconomy Awards Gala Slideshow

We at Xconomy were thrilled to see such a great turnout at our first-ever Awards Gala—350 people from the Boston life sciences community filled a Hynes Convention Center ballroom. As Bob Buderi, our founder and editor-in-chief, said in his opening remarks on September 26 before a sold-out crowd: We clearly struck a chord. Top scientists, […]

Posted in Boston, Boston blog main, Boston top stories, Boulder/Denver blog main, Detroit blog main, Indiana blog main, National blog main, National top stories, New York blog main, Raleigh-Durham blog main, San Diego blog main, San Francisco blog main, Seattle blog main, Texas blog main, Wisconsin blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Celebrating Boston Life Sciences: Xconomy Awards Gala Slideshow

Startup Builders, IPO Closers & More: Meet Xconomy’s CEO Award Finalists

There are many ways to stand out as a biotech CEO, from getting a company started in the first place to pushing its first drug over the finish line. Those differences are what we noticed when going through the nominations from you, the readers, for the top Boston biotech CEO, as part of the first-ever […]

Posted in Boston, Boston blog main, Boston top stories, Boulder/Denver blog main, Detroit blog main, Indiana blog main, National blog main, National top stories, New York blog main, Raleigh-Durham blog main, San Diego blog main, San Francisco blog main, Seattle blog main, Texas blog main, Wisconsin blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Startup Builders, IPO Closers & More: Meet Xconomy’s CEO Award Finalists

East Coast Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More

What summer doldrums? It’s still not even Labor Day, yet the deals are already coming fast and furious. So fire up the grill and read on for some Series A rounds, crossover investments, data readouts, option-to-buy deals and more. —As Xconomy reported this week, a stealthy Cambridge, MA-based startup called X4 Pharmaceuticals raised a $37.5 […]

Posted in Boston, Boston blog main, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More

Ragan Reunites Ex-Genzymers at X4 Pharma to Battle Cancer

Several years ago, Genzyme developed a drug called plerixafor (Mozobil) that’s used to help with bone marrow transplants. Now a group of folks that helped push that drug forward have reunited for a new effort—to use a similar type of therapy for solid tumors and rare diseases. As Xconomy reported earlier today, X4 Pharmaceuticals was […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Ragan Reunites Ex-Genzymers at X4 Pharma to Battle Cancer

Stealthy X4 Pharma, Aided by Termeer, Other Ex-Genzymers, Nabs $37M+

Former Genzyme CEO Henri Termeer has been active as an advisor and investor in the Boston biotech scene the past few years, forming ties with companies like Moderna Therapeutics, Lysosomal Therapeutics, Aura Biosciences, and others. The latest startup to add to his list is X4 Pharmaceuticals, which apparently has raised $37.5 million, according to a […]

Posted in Boston, Boston blog main, National blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Stealthy X4 Pharma, Aided by Termeer, Other Ex-Genzymers, Nabs $37M+